GlobeNewswire Inc | Aug 7, 2020 03:00AM EDT

August 07, 2020

SINGAPORE, Aug. 07, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced its presentation at the BTIG Virtual Biotechnology Conference. Dr Carl Firth, Chief Executive Officer, and Stephen Doyle, Chief Business Officer, are scheduled to participate in a fireside chat on Monday, 10 August, 2020 at 09:00am ET. The conference will be held from 10-11 August 2020.

The presentation deck used at the conference will be available in the Investors section of ASLANs website at www.aslanpharma.comfollowing the event.

Ends

Media and IR contacts

Emma Thompson Robert UhlSpurwing Communications Westwicke PartnersTel: +65 6751 2021 Tel: +1 858 356 5932Email: ASLAN@spurwingcomms.com Email: robert.uhl@westwicke.com

About ASLAN Pharmaceuticals ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497) is a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first in class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and a small molecule inhibitor targeting oncology. ASLANs partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL. For additional information please visit www.aslanpharma.com.

Forward looking statements

This release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the Companys business strategy, the Companys plans to develop and commercialise its product candidates, the safety and efficacy of the Companys product candidates, the Companys plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for the Companys product candidates. The Companys estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Companys business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation the risk factors described in the Companys U.S. Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Companys Form 20-F filed with the U.S. Securities and Exchange Commission (the SEC) on April 16, 2020. All statements other than statements of historical fact are forward-looking statements.

All statements other than statements of historical fact are forward-looking statements. The words believe, may, might, could, will, aim, estimate, continue, anticipate, intend, expect, plan, or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.